To recapitulate BRCA2 deficiency in pancreatic cancer, Brca2 was knocked out by CRISPR/Cas9 in a murine PDAC cell line derived from late-stage primary tumors from an autochthonous mouse model of KrasG12D and Trp53R172H-mutated PDAC (KPC)23 (Fig. 1f). This evidence concerns the gene BRCA2 and pancreatic neoplasm.